Samsung Bioepis Begins Commercialization of BYOOVIZ®, Biosimilar to Lucentis (Ranibizumab), in Europe

INCHEON, Korea--(BUSINESS WIRE)-- #biosimilars--Samsung Bioepis announced that the company has begun direct commercialization of BYOOVIZ®, a biosimilar to Lucentis (ranibizumab), in Europe.